ResMed completes $340m Noctrix Health acquisition
Noctrix Health’s lead product, Nidra, targets the peroneal nerves to address the symptoms of restless leg syndrome.
04 June 2026
04 June 2026
Noctrix Health’s lead product, Nidra, targets the peroneal nerves to address the symptoms of restless leg syndrome.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.